Advertisement
Advertisement

Prostate

Displaying results 1-10 of 50

  • This article reviews the current state of end-of-life care, analyzes the clinical and financial impact of palliative care, and proposes areas of future research and development.

  • Germline or somatic inactivating mutations in BRCA1 or BRCA2 or other genes involved in the homologous recombination (HR) pathway of DNA repair collectively occur in as much as 20%–25% of advanced prostate cancers. This article discusses the current understanding of the genomic landscape of prostate cancer, focusing on the occurrence of DNA repair mutations and the therapeutic opportunities this presents.

  • In this issue of The Oncologist, Agarwal et al. report negative results from a phase I trial of LFA102. Although "negative" in terms of antitumor activity, the study provides useful pharmacokinetic and pharmacodynamic information. Future trials evaluating PRLR blockers alone and in combination with other agents may still be warranted in patients with breast and prostate cancer.

  • Prostate cancer prognostic assays can provide information about disease aggressiveness that may improve decisions about use of active surveillance versus invasive treatment in early stage disease. This study found that the assay strategy could result in increased quality-adjusted survival and decreased cost compared with usual care. The findings demonstrate the potential for prognostic assays in this clinical setting, in which many patients currently receive invasive treatment but derive limited clinical benefit.